# Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

> **NCT03301350** · PHASE2 · COMPLETED · sponsor: **University of Wisconsin, Madison** · enrollment: 29 (actual)

## Conditions studied

- Breast Cancer
- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Pegfilgrastim
- **DRUG:** Filgrastim

## Key facts

- **NCT ID:** NCT03301350
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-07
- **Primary completion:** 2020-03-23
- **Final completion:** 2022-02-07
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03301350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03301350, "Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT03301350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*